Cluster Headache Attacks Treated for Up Three Months with Subcutaneous Sumatriptan (6 mg)
Cluster Headache Attacks Treated for Up Three Months with Subcutaneous Sumatriptan (6 mg)
复制标题
皮下注射舒马曲坦（6 毫克）治疗丛集性头痛发作长达三个月
DOI：
--
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
D. Noronha
中科院分区：
文献类型：
--
作者：
K. Ekbom;A. Krabbe;G. Micelli;A. Prusiński;J. Cole;A. Pilgrim;D. Noronha
在一项为期24个月的开放性研究的前三个月，评估皮下注射6 mg舒马曲坦长期急性治疗丛集性头痛的安全性和有效性，138名患者每天最多注射6 mg舒马曲坦治疗2次发作。共治疗了6353次发作。在28%的舒马曲坦治疗发作中报告的不良事件与偏头痛长期试验中观察到的不良事件在性质上相似。他们的发病率并没有随着舒马曲坦的频繁使用而增加。对生命体征、ECG记录或实验室参数没有临床显著的治疗效应。头痛缓解（从非常严重，严重或中度疼痛减轻到轻度或无疼痛）在15分钟时，平均96%的治疗发作。没有迹象表明快速耐受，反应速度下降，或长期治疗的攻击频率增加。这项研究表明，在长期使用中，皮下注射6 mg舒马曲坦是一种耐受性良好且有效的丛集性头痛急性治疗方法。
In the first three months of a 24–month open study to assess the safety and efficacy of subcutaneous sumatriptan 6 mg in the long-term acute treatment of cluster headache, 138 patients treated a maximum of two attacks daily each with a single 6 mg injection. A total of 6353 attacks were treated. Adverse events, reported in 28% of sumatriptan-treated attacks, were qualitatively similar to those seen in migraine long-term trials. Their incidence did not increase with frequent use of sumatriptan. There were no clinically significant treatment effects on vital signs, ECG recordings or laboratory parameters. Headache relief (a reduction from very severe, severe or moderate pain to mild or no pain) at 15 min was obtained for a median of 96% of attacks treated. There was no indication of tachyphylaxis, decrease in the speed of response, or increased frequency of attacks with long-term treatment. This study demonstrated that, in long-term use, subcutaneous sumatriptan 6 mg is a well-tolerated and effective acute treatment for cluster headache.